Thermo Fisher and Qiagen Agree Terms for Acquisition
Thermo Fisher Scientific Inc. and QIAGEN N.V. have announced that they have entered into an amendment to their acquisition agreement under which Thermo Fisher has commenced a tender offer to acquire all of the ordinary shares of QIAGEN.
The amendment increases the original offer price of €39.00 to a new price of €43.00 per QIAGEN share in cash, a premium of about 35%. QIAGEN’s Supervisory Board and Managing Board have reaffirmed their support for the offer and their recommendation that all QIAGEN shareholders accept and tender all of their shares during the offer period. The transaction is expected to complete in the first half of 2021.
Marc N. Casper, Chairman, President and Chief Executive Officer of Thermo Fisher Scientific, said, “Industry dynamics have changed considerably in the past few months, creating tailwinds and headwinds for our businesses. Both of our companies are playing important roles in helping customers to battle the COVID-19 pandemic. After careful consideration, we’ve decided to increase our offer for QIAGEN to reflect the fair value of the business given the current environment.”